Cost-Effectiveness Analysis of Abiraterone Acetate as Second Line Treatment for Metastatic Castration-Resistant Prostate Cancer After Docetaxel Treatment in Japan
Abstract
Authors
H. Shibahara T. Shiroiwa K. Nakamura K. Shimozuma